OPHL.F Stock Overview
Produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 6/6 |
Ono Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥11.35 |
| 52 Week High | JP¥19.09 |
| 52 Week Low | JP¥10.26 |
| Beta | 0.16 |
| 11 Month Change | -10.63% |
| 3 Month Change | -22.79% |
| 1 Year Change | -40.54% |
| 33 Year Change | -44.82% |
| 5 Year Change | -38.24% |
| Change since IPO | -64.59% |
Recent News & Updates
Recent updates
Shareholder Returns
| OPHL.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.7% | 2.8% | 2.2% |
| 1Y | -40.5% | 11.8% | 32.6% |
Return vs Industry: OPHL.F underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: OPHL.F underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| OPHL.F volatility | |
|---|---|
| OPHL.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OPHL.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine OPHL.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1717 | 3,853 | Gyo Sagara | www.ono-pharma.com |
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis.
Ono Pharmaceutical Co., Ltd. Fundamentals Summary
| OPHL.F fundamental statistics | |
|---|---|
| Market cap | US$5.30b |
| Earnings (TTM) | US$614.36m |
| Revenue (TTM) | US$3.13b |
8.6x
P/E Ratio1.7x
P/S RatioIs OPHL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OPHL.F income statement (TTM) | |
|---|---|
| Revenue | JP¥484.30b |
| Cost of Revenue | JP¥119.24b |
| Gross Profit | JP¥365.06b |
| Other Expenses | JP¥269.93b |
| Earnings | JP¥95.13b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 03, 2025
| Earnings per share (EPS) | 202.52 |
| Gross Margin | 75.38% |
| Net Profit Margin | 19.64% |
| Debt/Equity Ratio | 19.0% |
How did OPHL.F perform over the long term?
See historical performance and comparison